Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
McKesson
AstraZeneca
Dow

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR EDARAVONE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Edaravone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00153946 ↗ Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Japan Cardiovascular Research Foundation Phase 4 2004-08-01 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00153946 ↗ Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Combination Therapy for Acute Ischemic Stroke Study Group Phase 4 2004-08-01 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00200356 ↗ Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke Completed Mitsubishi Tanabe Pharma Corporation Phase 4 2004-08-01 This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
NCT00265239 ↗ Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Japan Heart Foundation Phase 4 2001-04-01 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
NCT00265239 ↗ Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Kumamoto University Phase 4 2001-04-01 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Edaravone

Condition Name

Condition Name for Edaravone
Intervention Trials
ALS 8
Healthy Adult Subjects 7
Amyotrophic Lateral Sclerosis 7
Acute Ischemic Stroke 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Edaravone
Intervention Trials
Motor Neuron Disease 15
Amyotrophic Lateral Sclerosis 15
Stroke 13
Ischemic Stroke 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Edaravone

Trials by Country

Trials by Country for Edaravone
Location Trials
United States 101
Japan 62
China 46
Canada 23
Italy 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Edaravone
Location Trials
Maryland 5
Colorado 5
Arizona 5
Wisconsin 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Edaravone

Clinical Trial Phase

Clinical Trial Phase for Edaravone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Edaravone
Clinical Trial Phase Trials
Completed 26
Not yet recruiting 12
Recruiting 12
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Edaravone

Sponsor Name

Sponsor Name for Edaravone
Sponsor Trials
Mitsubishi Tanabe Pharma Corporation 17
Mitsubishi Tanabe Pharma Development America, Inc. 4
Jiangsu Simcere Pharmaceutical Co., Ltd. 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Edaravone
Sponsor Trials
Other 91
Industry 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Colorcon
Baxter
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.